Debashis Sarker

8.0k total citations
132 papers, 2.3k citations indexed

About

Debashis Sarker is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Debashis Sarker has authored 132 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Oncology, 38 papers in Molecular Biology and 36 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Debashis Sarker's work include Pancreatic and Hepatic Oncology Research (20 papers), Hepatocellular Carcinoma Treatment and Prognosis (20 papers) and PI3K/AKT/mTOR signaling in cancer (14 papers). Debashis Sarker is often cited by papers focused on Pancreatic and Hepatic Oncology Research (20 papers), Hepatocellular Carcinoma Treatment and Prognosis (20 papers) and PI3K/AKT/mTOR signaling in cancer (14 papers). Debashis Sarker collaborates with scholars based in United Kingdom, United States and France. Debashis Sarker's co-authors include Johann S. de Bono, Timothy A. Yap, Alison Reid, Paul Workman, Paul J. Ross, D. Papadatos-Pastos, Roy Rabbie, Debra H. Josephs, Mark Bower and Udai Banerji and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Debashis Sarker

126 papers receiving 2.3k citations

Peers

Countries citing papers authored by Debashis Sarker

Since Specialization

Citations

This map shows the geographic impact of Debashis Sarker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Debashis Sarker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Debashis Sarker more than expected).

Fields of papers citing papers by Debashis Sarker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Debashis Sarker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Debashis Sarker. The network helps show where Debashis Sarker may publish in the future.

Co-authorship network of co-authors of Debashis Sarker

This figure shows the co-authorship network connecting the top 25 collaborators of Debashis Sarker. A scholar is included among the top collaborators of Debashis Sarker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Debashis Sarker. Debashis Sarker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Prognosis of NETs has there been improvement over the last 30 years	Neuroendocrinology	Debashis Sarker, Arkadiusz Rak et al.	0
2	Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors	Journal of Clinical Oncology	Jia Liu, Anna Minchom et al.	1
3	1515MO Clinical outcomes and PD-L1 expression analyses from a trial of mRNA-4359 plus pembrolizumab in checkpoint inhibitor-resistant/refractory (CPI-R/R) melanoma	Annals of Oncology	Adnan Khattak, Debashis Sarker et al.	0
4	679TiP Cancer Research UK phase I/IIa trial of the prostaglandin E2 (PGE2) receptor 4 (EP4) antagonist HTL0039732 as monotherapy and in combination with immunotherapy in patients (pts) with advanced solid tumors	Annals of Oncology	Debashis Sarker, Carol S. Leung et al.	3
5	Dendrimer-enhanced (DEP) SN38 (DEP irinotecan) in patients (pts) with advanced solid tumors: A phase 1/2 trial.	Journal of Clinical Oncology	Jia Liu, Anna Minchom et al.	1
6	The global leadership into malnutrition criteria reveals a high percentage of malnutrition which influences overall survival in patients with gastroenteropancreatic neuroendocrine tumours	Journal of Neuroendocrinology	Monique E. van Leerdam, Margot Tesselaar et al.	7
7	Neuroendocrine neoplasms: Consensus on a patient care pathway	Journal of Neuroendocrinology	Alia Munir, D. Mark Pritchard et al.	0
8	PP.42 Phase 1 Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced NSCLC	Journal of Thoracic Oncology	Byoung Chul Cho, Grace K. Dy et al.	1
9	A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer	British Journal of Cancer	Rebecca Kristeleit, Ruth Plummer et al.	22
10	A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer	Clinical Cancer Research	Robert H. Jones, Ruth Plummer et al.	27
11	A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer	Clinical Cancer Research	Debashis Sarker, Nancy A. Dawson et al.	22
12	Apoptosis in the Pancreatic Cancer Tumor Microenvironment—The Double-Edged Sword of Cancer-Associated Fibroblasts	Cells	Joy Burchell, Francesco Dazzi et al.	13
13	Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison	Advances in Therapy	Jörg Trojan, Patrick Mollon et al.	11
14	Margin ACcentuation for resectable Pancreatic cancer using Irreversible Electroporation – Results from the MACPIE-I study	European Journal of Surgical Oncology	Abdul Hakeem, M. Papoulas et al.	4
15	Assessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)	Annals of Oncology	Thomas Yau, Philippe Merle et al.	4
16	Phase 1 safety and clinical activity of BLU-554 in advanced hepatocellular carcinoma (HCC)	Annals of Oncology	Debashis Sarker, Teresa Macarulla et al.	17
17	The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer	Clinical Cancer Research	Udai Banerji, D. Ross Camidge et al.	176
18	An analysis of the risk of toxicity associated with participation in phase 1 oncology trials of novel molecularly targeted agents (mta) at the drug development unit, royal marsden hospital	Annals of Oncology	David Olmos, M. Puglisi et al.	5
19	Use of gene expression microarrays to identify novel pharmacodynamic biomarkers of phosphatidylinositide-3’-kinase (PI3K) inhibition	Cancer Research	Debashis Sarker, Paul A. Clarke et al.	1
20	The immunological effects of concomitant highly active antiretroviral therapy and liposomal anthracycline treatment of HIV-1-associated Kaposi's sarcoma	AIDS	Simon Portsmouth, Debashis Sarker et al.	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact